Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan-Dec:33:9636897241283539.
doi: 10.1177/09636897241283539.

Exploration of Efficient HLA Haplotypes by Comparing the Proportion of Applicable Populations

Paeng Sunwoong  1 , Yeri Alice Rim  2   3   4 , Yeowon Sohn  5 , Yoojun Nam  5   6 , Ji Hyeon Ju  2   3   4   6
Affiliations
Review

Exploration of Efficient HLA Haplotypes by Comparing the Proportion of Applicable Populations

Paeng Sunwoong et al. Cell Transplant. 2024 Jan-Dec.

Abstract

With the aging population, the incidence of degenerative diseases such as dementia and arthritis is on the rise. To combat these diseases, cell therapies using induced pluripotent stem cells (iPSCs) are being developed worldwide. However, challenges such as high development costs and immune compatibility persist. Thus, methods such as generating patient-specific iPSCs or genetically edited iPSCs with deleted immune-related genes are being researched. Applying these approaches is limited due to high cost and safety concerns of gene editing. Therefore, we focused on an alternative method using human leukocyte antigen (HLA)-homozygous cell lines, which could overcome immune rejection issues economically. We investigated diseases that could potentially be treated with cell therapy and identified which HLA-homozygous cell lines could be most effectively used for the efficient production of therapeutic cell lines. The results of the study showed that cell therapy could be applied to a wide range of diseases, and expanding the population that can benefit from HLA-homozygous iPSC lines could help popularize these treatment methods. We highlight the necessity of a global HLA-homozygous iPSC bank.

Keywords: cell therapy; haplotype; human leukocyte antigen; immune compatibility; induced pluripotent stem cells.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Applicability rate of common human leukocyte antigen (HLA) haplotypes to diverse ethnic groups in the United States. This figure illustrates the percentage of the population within each ethnic group in the United States that could potentially benefit from homozygous cell lines of HLA haplotypes commonly found in their respective regions. The applicability rate is 12.63% for individuals of European descent, 16.77% for those of East Asian descent, and 11.83% for individuals of South American descent.
Figure 2.
Figure 2.
Map depicting common high-frequency human leukocyte antigen haplotypes in the surveyed regions.
See this image and copyright information in PMC

References

    1. El-Kadiry AE, Rafei M, Shammaa R. Cell therapy: types, regulation, and clinical benefits. Front Med. 2021;8:756029. - PMC - PubMed
    1. Madrid M, Sumen C, Aivio S, Saklayen N. Autologous induced pluripotent stem cell–based cell therapies: promise, progress, and challenges. Curr Protoc. 2021;1(3):e88. - PubMed
    1. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14(2):213–22. - PubMed
    1. Singh VK, Saini A, Kalsan M, Kumar N, Chandra R. Describing the stem cell potency: the various methods of functional assessment and in silico diagnostics. Front Cell Dev Biol. 2016;4:134. - PMC - PubMed
    1. Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M. Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 2018;15(1):36–45. - PMC - PubMed

MeSH terms

LinkOut - more resources